Art. -Nr.: HY-N0194

Asiatic acid

5 Cited Publications

Kundenbewertung

Based on 5 publication(s) in Google Scholar

Asiatic acid, a pentacyclic triterpene found in Centella asiatica (Centella asiatica), has anticancer activity. Asiatic acid induces apoptosis in melanoma cells and has barrier protective effects on human aortic endothelial cells (HAEC). Asiatic acid also has anti-inflammatory activity and inhibits tumor necrosis factor (TNF)-α-induced endothelial barrier dysfunction. Asiatic acid also inhibits NLRP3 inflammasome activation and NF-κB pathway, effectively inhibits inflammation in rats, and has neuroprotective effects in rat spinal cord injury (SCI) model.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.49%
CAS. Nr.: 464-92-6
Formel: C₃₀H₄₈O₅
Molecular Weight:488.70

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Asiatic acid Chemical Structure

CAS. Nr.: 464-92-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (5)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Parasite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
518A2	EC₅₀	21.9 μM Compound: AA	Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
8505C	EC₅₀	16.8 μM Compound: AA	Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
A2780	EC₅₀	28.2 μM Compound: AA	Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
A2780	EC₅₀	28.2 μM Compound: 1	Cytotoxicity against human A2780 cells incubated for 72 hrs by SRB assay Cytotoxicity against human A2780 cells incubated for 72 hrs by SRB assay	[PMID: 36780832]
A-375	EC₅₀	>30 μM Compound: 1	Cytotoxicity against human A-375 cells incubated for 72 hrs by SRB assay Cytotoxicity against human A-375 cells incubated for 72 hrs by SRB assay	[PMID: 36780832]
A-375	IC₅₀	50.33 μM Compound: AA; Asiatic Acid	Cytotoxicity against human A375 cells after 72 hrs by MTT assay Cytotoxicity against human A375 cells after 72 hrs by MTT assay	[PMID: 26974379]
A549	EC₅₀	26.2 μM Compound: AA	Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
A549	IC₅₀	>100 μM Compound: AA	Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
A549	IC₅₀	>20 μM Compound: AA	Inhibition of NFkappaB (unknown origin) expressed in human A549 cells co-transfected with pNFkappaB-Luc vector assessed as reduction in TNFalpha-induced NFkappaB transcriptional activity co-incubated for 7 hrs in presence of TNFalpha by bright-glo lucifer Inhibition of NFkappaB (unknown origin) expressed in human A549 cells co-transfected with pNFkappaB-Luc vector assessed as reduction in TNFalpha-induced NFkappaB transcriptional activity co-incubated for 7 hrs in presence of TNFalpha by bright-glo lucifer	[PMID: 31057738]
A549	IC₅₀	18.8 μM Compound: AA 6	Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 28754470]
A549	IC₅₀	37.81 μM Compound: AA 6	Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 28754470]
A549	IC₅₀	41.02 μM Compound: AA	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 31057738]
BJ	IC₅₀	88.7 μM Compound: AA; Asiatic Acid	Cytotoxicity against human BJ cells after 72 hrs by MTT assay Cytotoxicity against human BJ cells after 72 hrs by MTT assay	[PMID: 26974379]
CHO	EC₅₀	>10 μM Compound: Asiatic acid	Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay	[PMID: 19911773]
COS-1	EC₅₀	0 μM Compound: Asiatic acid	Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay	[PMID: 19911773]
Epithelial cell	IC₅₀	>20 μM Compound: asiatic acid	Antiproliferative activity against mouse +SA mammary epithelial cells after 4 days by MTT assay Antiproliferative activity against mouse +SA mammary epithelial cells after 4 days by MTT assay	[PMID: 18826277]
H9	IC₅₀	9 μg/mL Compound: 8	Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA	[PMID: 9748372]
HeLa	IC₅₀	37.26 μM Compound: AA	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25151580]
HeLa	IC₅₀	4 μM Compound: AA 6	Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 28754470]
HeLa	IC₅₀	52.47 μM Compound: AA 6	Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28754470]
HeLa	IC₅₀	52.47 μM Compound: AA; Asiatic Acid	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 26974379]
HeLa	IC₅₀	91.07 μM Compound: AA	Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
HepG2	IC₅₀	>10 μM Compound: 24	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 27797185]
HepG2	IC₅₀	34.9 μM Compound: AA	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 25151580]
HepG2	IC₅₀	35.37 μM Compound: AA	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 31057738]
HT-29	EC₅₀	>30 μM Compound: AA	Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
HT-29	EC₅₀	>30 μM Compound: 1	Cytotoxicity against human HT-29 cells incubated for 72 hrs by SRB assay Cytotoxicity against human HT-29 cells incubated for 72 hrs by SRB assay	[PMID: 36780832]
HT-29	IC₅₀	64.3 μM Compound: AA; Asiatic Acid	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 26974379]
HT-29	IC₅₀	64.33 μM Compound: AA 6	Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28754470]
HUVEC	IC₅₀	>100 μM Compound: AA	Cytotoxicity against human HUVEC cells after 48 hrs by MTT assay Cytotoxicity against human HUVEC cells after 48 hrs by MTT assay	[PMID: 25151580]
HUVEC	IC₅₀	>100 μM Compound: AA 6	Cytotoxicity in HUVEC cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in HUVEC cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 28754470]
Jurkat	IC₅₀	37.17 μM Compound: AA; Asiatic Acid	Cytotoxicity against human Jurkat cells after 72 hrs by XTT assay Cytotoxicity against human Jurkat cells after 72 hrs by XTT assay	[PMID: 26974379]
L02	IC₅₀	>50 μM Compound: AA	Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay	[PMID: 31057738]
MCF7	EC₅₀	>30 μM Compound: AA	Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
MCF7	EC₅₀	>30 μM Compound: 1	Cytotoxicity against human MCF7 cells incubated for 72 hrs by SRB assay Cytotoxicity against human MCF7 cells incubated for 72 hrs by SRB assay	[PMID: 36780832]
MCF7	GI₅₀	19.1 μM Compound: AA 6	Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 28754470]
MCF7	IC₅₀	>10 μM Compound: 24	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 27797185]
MCF7	IC₅₀	32.8 μM Compound: AA 6	Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 28754470]
MCF7	IC₅₀	67.58 μM Compound: AA	Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
MCF7	IC₅₀	68.5 μM Compound: AA; Asiatic Acid	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 26974379]
MDA-MB-231	GI₅₀	18.1 μM Compound: AA 6	Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 28754470]
MGC-803	IC₅₀	22.57 μM Compound: AA	Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 25151580]
MIA PaCa-2	IC₅₀	50.67 μM Compound: AA; Asiatic Acid	Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay	[PMID: 26974379]
NCI-H460	IC₅₀	39.55 μM Compound: AA	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 25151580]
NCI-H460	IC₅₀	44.82 μM Compound: AA	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 31057738]
NCI-N87	IC₅₀	>10 μM Compound: 24	Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay	[PMID: 27797185]
NIH3T3	EC₅₀	26.2 μM Compound: AA	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
NIH3T3	EC₅₀	26.2 μM Compound: 1	Cytotoxicity against mouse NIH/3T3 cells incubated for 72 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells incubated for 72 hrs by SRB assay	[PMID: 36780832]
PC-3	IC₅₀	53.6 μM Compound: AA 6	Cytotoxicity in human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity in human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 28754470]
PC-3	IC₅₀	67.25 μM Compound: AA; Asiatic Acid	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 26974379]
RAW264.7	IC₅₀	74.8 μM Compound: 4	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs	[PMID: 21353543]
RAW264.7	IC₅₀	8.6 μM Compound: 4	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method	[PMID: 21353543]
Sf21	IC₅₀	>40 μM Compound: 25	Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis	[PMID: 31774676]
SGC-7901	IC₅₀	36.8 μM Compound: AA 6	Cytotoxicity in human SGC7901 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity in human SGC7901 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 28754470]
T-24	IC₅₀	33.72 μM Compound: AA 6	Cytotoxicity in human T24 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human T24 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 28754470]
T-24	IC₅₀	43.97 μM Compound: AA	Cytotoxicity against human T24 cells after 48 hrs by MTT assay Cytotoxicity against human T24 cells after 48 hrs by MTT assay	[PMID: 31057738]

In Vitro

Asiatic acid exerts barrier stabilizing effects against TNF-α by maintaining adherens junctions (AJs) and inhibiting tight junction (TJ) redistribution^[2].
Asiatic acid (40 μM) stabilizes F-actin and diphosphate-MLC at the cell periphery and prevents their rearrangement stimulated by TNF-α (10 ng/mL; 1 h). However, Asiatic acid (10-30 μM; 6 h) cannot reduce F-actin aggregation^[2].
Asiatic acid (40 μM; 6 h) preserves the network structure of cell-cell contact areas and abolishes TNF-α-induced structural reorganization of vascular endothelial (VE)-cadherin and β-catenin^[2].
However, Asiatic acid (10-40 μM; 6 h) had no inhibitory effect on endothelial cell permeability increased by cytochalasin D (5 μM; 15 min). Asiatic acid increases the diphosphorylation of myosin light chain (MLC)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Asiatic acid (5-75 mg/kg; intragastric gavage once daily) effectively inhibited pelvic inflammatory disease (PID) in rats in a pathogen-induced disease model and exerted antioxidant and anti-inflammatory effect^[3].
Asiatic acid (30 mg/kg, 75 mg/kg; intragastric injection, once daily) has neuroprotective effects on spinal cord injury (SCI) in rats by inhibiting inflammation and oxidative stres^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 464-92-6
Appearance Solid
Molecular Weight 488.70
Formel C₃₀H₄₈O₅
Color White to off-white
SMILES

C[C@@]1(CO)[C@@H](O)[C@H](O)C[C@]2(C)[C@@]3([H])CC=C4[C@]5([H])[C@@H](C)[C@H](C)CC[C@@](C(O)=O)5CC[C@](C)4[C@@](C)3CC[C@@]12[H]
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (5)

All Cell Proliferation/Viability AssayFlow CytometryIn Vivo Efficacy StudyIHC

Sort by:

Journal Impact Factor

Acta Pharmacol Sin

Asiatic acid promotes CD8+ T cell-mediated antitumor immunity by targeting HDAC8/CXCL10 axis in hepatocellular carcinoma. [Abstract]

2026 Feb 5. PMID: 41644738

Asiatic acid purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2026 Feb 5. [Abstract]

The cell viability of human normal liver cells (L02), human HCC cells (HuH7), and murine hepatoma cells (Hepa 1-6, H22) treated with Asiatic acid (AA) (20-120 μM; 48 h).

Asiatic acid purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2026 Feb 5. [Abstract]

Asiatic acid (AA) (40 μM; 24 h) markedly increased apoptosis rate of HCC cells.

Asiatic acid purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2026 Feb 5. [Abstract]

Asiatic acid (AA) (50 mg/kg; i.g.; once daily) reduced the tumor weight and volume in C57BL/6J subcutaneous allograft tumor models.

Asiatic acid purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2026 Feb 5. [Abstract]

Asiatic acid (AA) (50 mg/kg; i.g.; once daily) prolonged the overall survival of C57BL/6J tumor-bearing mice.

Asiatic acid purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2026 Feb 5. [Abstract]

Asiatic acid (AA) (50 mg/kg; i.g.; once daily) significantly increased cleaved caspase-3 and decreased Ki-67 levels in tumor tissues of C57BL/6J tumor-bearing mice.
Acta Pharmacol Sin

Asiatic acid alleviates ischemic myocardial injury in mice by modulating mitophagy- and glycophagy-based energy metabolism. [Abstract]

2022 Jun;43(6):1395-1407. PMID: 34522006
Pharmaceuticals (Basel)

Exploring the Mechanism of Asiatic Acid against Atherosclerosis Based on Molecular Docking, Molecular Dynamics, and Experimental Verification. [Abstract]

2024 Jul 22;17(7):969. PMID: 39065817
Cancers (Basel)

Synergistic Combination of Luteolin and Asiatic Acid on Cervical Cancer In Vitro and In Vivo. [Abstract]

2023 Jan 16;15(2):548. PMID: 36672499
Naunyn Schmiedebergs Arch Pharmacol

Serum-based untargeted metabolomics reveals the therapeutic mechanism of asiatic acid against atherosclerosis in ApoE-/- mice. [Abstract]

2026 Jun 27. PMID: 42363947

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 250 mg/mL (511.56 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0462 mL

10.2312 mL

20.4625 mL

5 mM

0.4092 mL

2.0462 mL

4.0925 mL

10 mM

0.2046 mL

1.0231 mL

2.0462 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.25 mg/mL (4.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (22.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (4.26 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.26 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Park BC, et al. Asiatic acid induces apoptosis in SK-MEL-2 human melanoma cells. Cancer Lett. 2005 Jan 31;218(1):81-90. [Content Brief]

[2]. Huang SS, et al. Antinociceptive activities and the mechanisms of anti-inflammation of asiatic Acid in mice. Evid Based Complement Alternat Med. 2011;2011:895857. [Content Brief]

[3]. Fong LY, et al. Asiatic acid stabilizes cytoskeletal proteins and prevents TNF-α-induced disorganization of cell-cell junctions in human aortic endothelial cells. Vascul Pharmacol. 2019 Jun;117:15-26. [Content Brief]

[4]. Jiang W, et al. Neuroprotective effect of asiatic acid against spinal cord injury in rats. Life Sci. 2016 Jul 15;157:45-51. [Content Brief]

[5]. Kong D, et al. Protective effects of Asiatic acid against pelvic inflammatory disease in rats. Exp Ther Med. 2019 Jun;17(6):4687-4692. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0462 mL	10.2312 mL	20.4625 mL	51.1561 mL
	5 mM	0.4092 mL	2.0462 mL	4.0925 mL	10.2312 mL
	10 mM	0.2046 mL	1.0231 mL	2.0462 mL	5.1156 mL
	15 mM	0.1364 mL	0.6821 mL	1.3642 mL	3.4104 mL
	20 mM	0.1023 mL	0.5116 mL	1.0231 mL	2.5578 mL
	25 mM	0.0818 mL	0.4092 mL	0.8185 mL	2.0462 mL
	30 mM	0.0682 mL	0.3410 mL	0.6821 mL	1.7052 mL
	40 mM	0.0512 mL	0.2558 mL	0.5116 mL	1.2789 mL
	50 mM	0.0409 mL	0.2046 mL	0.4092 mL	1.0231 mL
	60 mM	0.0341 mL	0.1705 mL	0.3410 mL	0.8526 mL
	80 mM	0.0256 mL	0.1279 mL	0.2558 mL	0.6395 mL
	100 mM	0.0205 mL	0.1023 mL	0.2046 mL	0.5116 mL

Keywords

Asiatic acid

5 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Asiatic acid

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Terpenoids Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antiparasitic Compound library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Cell Death Library

Inflammasomes related Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Fatty Acids Compound Library

Miao Ethnicity Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Cosmetic Ingredient Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Asiatic acid

Alle Parasite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (5)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Asiatic acid Related Classifications

HY-N0194 Related Classifications